{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:11:49Z","timestamp":1783793509767,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stem cell collection for autologous stem cell transplant after induction therapy remains standard for multiple myeloma (MM). Motixafortide, a novel C\u2010X\u2010C motif chemokine receptor 4 (CXCR4) antagonist with prolonged receptor occupancy compared to plerixafor, potentially enhances stem cell mobilization. Direct comparison with plerixafor in MM has not been reported. This quality initiative compares motixafortide\u2009+\u2009granulocyte colony\u2010stimulating factor (G\u2010CSF) versus plerixafor\u2009+\u2009G\u2010CSF for stem cell mobilization in MM patients at a single center, assessing feasibility, collection\/mobilization outcomes, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design and Methods<\/jats:title>\n                    <jats:p>A prospective cohort of 30\u2009MM patients receiving motixafortide\u2009+\u2009G\u2010CSF was compared to a contemporary, retrospective cohort of covariate\u2010matched 30 patients receiving plerixafor\u2009+\u2009G\u2010CSF. Institutional apheresis procedure practices were followed. Primary outcomes included number of collection days, apheresis procedure duration, and adverse events requiring intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty\u2010nine of 30 motixafortide patients completed mobilization. CD34+ stem cell\u00a0yields and apheresis procedure times were similar between groups; 27 patients per group reached collection targets in 1\u2009day. Motixafortide recipients experienced more frequent adverse reactions (ARs) than plerixafor recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this first real\u2010world comparison, use of motixafortide was feasible but not superior to plerixafor for MM mobilization. Motixafortide was associated with substantially higher rates of injection\u2010site and systemic ARs requiring intervention and imposed additional workflow demands for premedication and post\u2010injection monitoring. Due to the non\u2010superiority of motixafortide, decreasing acquisition costs for plerixafor and motixafortide's higher resource utilization, our institution favors continuing plerixafor as the default for MM mobilization. We reserve motixafortide for select patients, with ongoing evaluation of poor mobilizers to clarify its role in collection and post\u2010transplant outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.70260","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:16:52Z","timestamp":1783790212000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real\u2010world experience"],"prefix":"10.1111","author":[{"given":"Sara","family":"Close","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-0224","authenticated-orcid":false,"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Abousamra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Konshina","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7597-5657","authenticated-orcid":false,"given":"Claire","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhayla","family":"Sarhan","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Geary","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Manis","sequence":"additional","affiliation":[{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Laboratory Medicine Boston Children's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Jun","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliff","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2711-5575","authenticated-orcid":false,"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"},{"name":"Department of Medicine Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle RA","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_9_3_1","unstructured":"American Cancer Society.Key statistics for multiple myeloma March 1st 2026.https:\/\/www.cancer.org\/cancer\/types\/multiple\u2010myeloma\/about\/key\u2010statistics.html"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo A","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_9_5_1","first-page":"10","article-title":"Optimal approach to stem cell mobilization in transplant\u2010eligible multiple myeloma patients","volume":"10","author":"Fitzsimons J","year":"2024","journal-title":"J Cancer Metastasis Treat"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30\u2009years","volume":"56","author":"Passweg JR","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G\u2010CSF versus cyclophosphamide plus G\u2010CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi S","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.12606","article-title":"Plerixafor on\u2010demand combined with chemotherapy and granulocyte colony\u2010stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs","volume":"164","author":"Milone G","year":"2014","journal-title":"Br J Haematol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.22179","article-title":"Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma","volume":"87","author":"Ozsan GH","year":"2012","journal-title":"Am J Hematol"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells\u2010definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter P","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic I","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_9_12_1","first-page":"1525","article-title":"A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony\u2010stimulating factor and \u2018on\u2010demand\u2019 plerixafor in multiple myeloma patients treated with novel agents","volume":"109","author":"Mina R","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00277-023-05170-0","article-title":"Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments","volume":"102","author":"Wei X","year":"2023","journal-title":"Ann Hematol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bmt.2012.281","article-title":"Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center","volume":"48","author":"Pozotrigo M","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"Bik To L","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103303","article-title":"Plerixafor strategies for autologous hematopoietic cell transplant mobilization: a comparison of efficacy and cost","volume":"61","author":"Chen KY","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231174304","article-title":"Innovations in hematopoietic stem\u2010cell mobilization: a review of the novel CXCR4 inhibitor motixafortide","volume":"14","author":"Crees ZD","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G\u2010CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees ZD","year":"2023","journal-title":"Nat Med"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia","volume":"189","author":"Ladikou EE","year":"2020","journal-title":"Br J Haematol"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G\u2010CSF versus placebo and G\u2010CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio JF","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_21_1","unstructured":"MOZOBIL\u00ae (plerixafor) injection for subcutaneous use. Prescribing information.https:\/\/products.sanofi.us\/mozobil\/mozobil.html"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","article-title":"Motixafortide: first approval","volume":"83","author":"Hoy SM","year":"2023","journal-title":"Drugs"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176057","article-title":"Comparison of cell\u2010based assays for the identification and evaluation of competitive CXCR4 inhibitors","volume":"12","author":"Van Hout A","year":"2017","journal-title":"PLoS One"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.febslet.2004.05.056","article-title":"Identification of a CXCR4 antagonist, a T140 analog, as an anti\u2010rheumatoid arthritis agent","volume":"569","author":"Tamamura H","year":"2004","journal-title":"FEBS Lett"},{"key":"e_1_2_9_25_1","first-page":"3656","article-title":"Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives","volume":"1","author":"Tamamura H","year":"2003","journal-title":"Org Biomol Chem"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2021-144296","article-title":"Motixafortide (BL\u20108040) and G\u2010CSF versus placebo and G\u2010CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma: the genesis trial","volume":"138","author":"Crees ZD","year":"2021","journal-title":"Blood"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.70260","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:16:57Z","timestamp":1783790217000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.70260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":25,"alternative-id":["10.1111\/trf.70260"],"URL":"https:\/\/doi.org\/10.1111\/trf.70260","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"2025-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"trf.70260"}}